Official websites use. Share sensitive information only on official, secure websites. Adult patients with acute lymphoblastic leukemia with low MRD positivity at week 16 form an intermediate-risk group. MolNE MRD results not just are borderline values with questionable relevance but also form an intermediate-risk group, assignment of which can be further improved by NGS.
Together, these patients were classified as molecular not evaluable MolNE , and their clinical characteristics are summarized in Table 1. This illusive discrepancy is attributable to sample selection: whereas the other studies are performed on unselected samples, we focused on samples with low-level RQ-PCR MRD with a therefore higher probability of false positive RQ-PCR results.
The authors thank all the patients and physicians for their participation in the study. Contribution: J. Conflict-of-interest disclosure: N. The remaining authors declare no competing financial interests. This section collects any data citations, data availability statements, or supplementary materials included in this article. As a library, NLM provides access to scientific literature. Blood Adv. Find articles by Johannes Koopmann.
Find articles by Heiko Trautmann. Find articles by Nael Alakel. Find articles by Joachim Beck. Find articles by Kathrin Nachtkamp. Find articles by Simon Raffel. Find articles by Andreas Viardot. Find articles by Klaus Wethmar. Find articles by Nikos Darzentas.
Find articles by Claudia D Baldus. All other rights reserved. Open in a new tab. Click here for additional data file. Similar articles.
